Kidswell Bio Corporation
Agreement to Subscribe for Shares Toward Joint Venture Formation by Four Companies Including Alfenax Biologics — Full-Scale Promotion of Domestic Biosimilar Manufacturing Infrastructure
Four companies have signed a share subscription agreement to transform Alfenax Biologics into a joint venture to establish domestic manufacturing capacity for biosimilars. The investment ratios remain as currently disclosed, with payment expected to be completed by 2026-11-25. Commercial production is targeted for the fiscal year ending March 2031.
Key Figures
- Share subscription agreement signing date: 2026-11-09
- Planned share subscription execution date: 2026-11-25
- Investment ratios: 45% / 45% / 7% / 3%
AI要約
Overview and Background
This matter announces that four companies, centered on Alfenax Biologics, have agreed to a share subscription agreement to establish a joint venture to build domestic manufacturing capacity in the biosimilar market. The parties will collaboratively construct and operate domestic manufacturing facilities and establish a domestically integrated CDMO structure for biopharmaceuticals and related products.
Future Schedule and Impact
The dates for signing the share subscription agreement and its execution have been disclosed; the joint venture structure will be established after payment completion. The impact on consolidated results from fiscal 2027 onward is expected to be minor, and a phased plan targeting the start of commercial production in the fiscal year ending March 2031 has been presented.
Kidswell Bio Corporation
Company overview · Stock price · Financial data · All IR
